Di Yu
Researcher at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Magnus Essand
- Mobile phone:
- +46 70 720 41 96
- E-mail:
- di.yu@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
More information is available to staff who log in.
Short presentation
Post Doc at Dept. Immunolgy, Genetics and Pathology
My research is focused on viruses-/T cell- based cancer therapy. Group leader: Magnus Essand
Publications
Selection of publications
- Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures (2013)
- Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors (2011)
Recent publications
- Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment (2023)
- CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- Complementarity-determining region clustering may cause CAR-T cell dysfunction (2023)
- A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products (2022)
All publications
Articles
- Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment (2023)
- CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- Complementarity-determining region clustering may cause CAR-T cell dysfunction (2023)
- A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products (2022)
- Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-turnor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response (2022)
- CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers (2022)
- Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses (2022)
- Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus (2021)
- IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma (2021)
- In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy (2021)
- Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19 (2021)
- Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer (2020)
- Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models (2018)
- Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses (2018)
- Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis (2018)
- CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis (2018)
- Modifying melanoma immune microenvironment by heterologous prime-boost vaccination with adenovirus and Modified Vaccinia Ankara virus vectors (2018)
- Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth (2018)
- CAR T-Cells with Induced Secretion of Helicobacter Pylori Neutrophil-Activating Protein (HP-NAP) Yields Improved Anti-Tumor Activity and Reduced Immunosuppression (2017)
- Adenovirus, Semliki Forest virus and vaccinia virus-induced immunogenic cell death augments oncolytic virus immunotherapy (2017)
- Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus (2017)
- Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity (2017)
- Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth (2017)
- Multiple viruses rely on the stress-induced protein ZC3H11A for efficient replication (2017)
- Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer (2017)
- Allogeneic dendritic cells (AlloDCs) transduced with an infection enhanced adenovirus as adjuvant for cancer immunotherapy (2016)
- Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer (2016)
- Long-term episomal gene transfer for safe engineering of T cells for adoptive cell therapy of cancer (2016)
- Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors (2016)
- A Multiplex Protein Panel Applied to Cerebrospinal Fluid Reveals Three New Biomarker Candidates in ALS but None in Neuropathic Pain Patients (2016)
- HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice (2016)
- Chondroitin Sulfate-Coated DNA-Nanoplexes Enhance Transfection Efficiency by Controlling Plasmid Release from Endosomes (2015)
- Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. (2015)
- Long-term episomal gene transfer for safe engineering of T-cells for adoptive cell therapy of cancer (2014)
- Allogeneic lymphocyte-licensed DCs expand T cells withimproved antitumor activity and resistance to oxidative stress andimmunosuppressive factors (2014)
- Allogeneic Lymphocyte-Licensed DCs Expand TCR/CAR-Engineered T Cells, Which Are Insensitive To Oxidative Stress and Immunosuppressive Factors (2014)
- A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells (2014)
- Vector-Encoded Helicobacter pylori Neutrophil-Activating Protein Promotes Maturation of Dendritic Cells with Th1 Polarization and Improved Migration (2014)
- Adenovirus Encoded Helicobacter pylori Neutrophil Activating Protein Promotes Maturation of DCs with Th-1 Polarization, Improved Antigen Presentation and Migration (2014)
- Tat‐PTD‐modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy (2013)
- An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors (2013)
- Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures (2013)
- Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells (2011)
- Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors (2011)
- Tumor antigen-loaded allogeneic dendritic cells augment therapeutic effect of adoptively transferred T-cells by altering tumor immune-microenvironment
- Therapeutic vaccination of HPV-associated tumors using pro-inflammatory allogeneic dendritic cells and an HPV-E6/E7-encoding vector
- Concomitant targeting of PD-1 or CD137 enhances the effect of adjuvant pro-inflammatory allogeneic dendritic cells.
- CD19 CAR T-cells with induced secretion of Helicobacter Pylori Neutrophil-Activating Protein (HP-NAP) yields improved anti-tumor activity and reduced immunosuppression
- Preclinical evaluation of CAR20(NAP)-T cells for B cell lymphoma
- Armed CAR-T cells directed against IL13Rα2 show potent activity against glioblastoma
- Complementary-determining region clustering causes CAR-T cell dysfunction
Books
